Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial
- P Harter (Author)
- P Wimberger (Author)
- A Okamoto (Author)
- A Reuss (Author)
- MC Lim (Author)
- MJ Rubio-Pérez (Author)
- MA Vardar (Author)
- G Scambia (Author)
- O Trédan (Author)
- S Hietanen (Author)
- N Colombo (Author)
- A Chudecka-Glaz (Author)
- Petru, E. (Author)
- S Lheureux (Author)
- E Van Nieuwenhuysen (Author)
- J Sehouli (Author)
- R Wenham (Author)
- K Ushijima (Author)
- S Indiviglio (Author)
- C Aghajanian (Author)
Activity: Talk, presentation or poster › Poster